Charles River Laboratories’ Dr. Alan K. Smith explains how early commercial planning, modular manufacturing, and AI-driven automation may accelerate scalable manufacturing for cell and gene therapies.
Alan K. Smith
Advertisement
Alan K. Smith, PhD, is executive cirector, Global Scientific Portfolio Management, Cell and Gene Therapy, at Charles River Laboratories.
Articles by Alan K. Smith
AI and automation may streamline cell and gene therapy manufacturing by reducing labor demands while improving efficiency and supporting scalable production, says Dr. Alan Smith of Charles River Laboratories.
Dr. Alan Smith of Charles River Laboratories explains why early manufacturing planning and scalable processes are critical to ensure successful commercialization of complex cell and gene therapies as part of his panel discussion at INTERPHEX 2026.
Advertisement
Latest Updated Articles
Advertisement
Advertisement